Logo image of OM

OUTSET MEDICAL INC (OM) Stock Fundamental Analysis

NASDAQ:OM - Nasdaq - US6901452069 - Common Stock - Currency: USD

12.25  +1.08 (+9.67%)

After market: 12.25 0 (0%)

Fundamental Rating

2

Overall OM gets a fundamental rating of 2 out of 10. We evaluated OM against 190 industry peers in the Health Care Equipment & Supplies industry. OM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, OM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OM has reported negative net income.
OM had a negative operating cash flow in the past year.
OM had negative earnings in each of the past 5 years.
In the past 5 years OM always reported negative operating cash flow.
OM Yearly Net Income VS EBIT VS OCF VS FCFOM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -46.40%, OM is doing worse than 65.61% of the companies in the same industry.
Looking at the Return On Equity, with a value of -477.18%, OM is doing worse than 86.77% of the companies in the same industry.
Industry RankSector Rank
ROA -46.4%
ROE -477.18%
ROIC N/A
ROA(3y)-47.4%
ROA(5y)-38.06%
ROE(3y)-228.02%
ROE(5y)-148.69%
ROIC(3y)N/A
ROIC(5y)N/A
OM Yearly ROA, ROE, ROICOM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 33.92%, OM is not doing good in the industry: 72.49% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of OM has grown nicely.
OM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y66.06%
GM growth 5YN/A
OM Yearly Profit, Operating, Gross MarginsOM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

OM does not have a ROIC to compare to the WACC, probably because it is not profitable.
OM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, OM has more shares outstanding
The debt/assets ratio for OM is higher compared to a year ago.
OM Yearly Shares OutstandingOM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
OM Yearly Total Debt VS Total AssetsOM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -5.07, we must say that OM is in the distress zone and has some risk of bankruptcy.
OM has a worse Altman-Z score (-5.07) than 68.25% of its industry peers.
OM has a Debt/Equity ratio of 7.36. This is a high value indicating a heavy dependency on external financing.
OM's Debt to Equity ratio of 7.36 is on the low side compared to the rest of the industry. OM is outperformed by 88.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 7.36
Debt/FCF N/A
Altman-Z -5.07
ROIC/WACCN/A
WACC8.33%
OM Yearly LT Debt VS Equity VS FCFOM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 5.69 indicates that OM has no problem at all paying its short term obligations.
The Current ratio of OM (5.69) is better than 81.48% of its industry peers.
A Quick Ratio of 4.38 indicates that OM has no problem at all paying its short term obligations.
OM has a better Quick ratio (4.38) than 74.07% of its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 4.38
OM Yearly Current Assets VS Current LiabilitesOM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for OM have decreased strongly by -301.29% in the last year.
The Revenue for OM has decreased by -12.80% in the past year. This is quite bad
Measured over the past years, OM shows a very strong growth in Revenue. The Revenue has been growing by 49.74% on average per year.
EPS 1Y (TTM)-301.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-840.68%
Revenue 1Y (TTM)-12.8%
Revenue growth 3Y3.48%
Revenue growth 5Y49.74%
Sales Q2Q%-3.41%

3.2 Future

The Earnings Per Share is expected to grow by 14.87% on average over the next years. This is quite good.
Based on estimates for the next years, OM will show a quite strong growth in Revenue. The Revenue will grow by 13.23% on average per year.
EPS Next Y72.53%
EPS Next 2Y32.76%
EPS Next 3Y21.75%
EPS Next 5Y14.87%
Revenue Next Year6.76%
Revenue Next 2Y9.71%
Revenue Next 3Y10.38%
Revenue Next 5Y13.23%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
OM Yearly Revenue VS EstimatesOM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
OM Yearly EPS VS EstimatesOM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2030 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OM Price Earnings VS Forward Price EarningsOM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OM Per share dataOM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

OM's earnings are expected to grow with 21.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.76%
EPS Next 3Y21.75%

More info and screens

0

5. Dividend

5.1 Amount

OM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OUTSET MEDICAL INC

NASDAQ:OM (5/2/2025, 8:15:52 PM)

After market: 12.25 0 (0%)

12.25

+1.08 (+9.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners46.67%
Inst Owner Change-1.62%
Ins Owners2.13%
Ins Owner Change26.93%
Market Cap217.07M
Analysts83.08
Price Target22.19 (81.14%)
Short Float %N/A
Short Ratio1.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.56%
Min EPS beat(2)10.2%
Max EPS beat(2)12.92%
EPS beat(4)2
Avg EPS beat(4)5.3%
Min EPS beat(4)-1.03%
Max EPS beat(4)12.92%
EPS beat(8)3
Avg EPS beat(8)-0.96%
EPS beat(12)4
Avg EPS beat(12)-3.32%
EPS beat(16)7
Avg EPS beat(16)-0.74%
Revenue beat(2)2
Avg Revenue beat(2)1.96%
Min Revenue beat(2)0.47%
Max Revenue beat(2)3.44%
Revenue beat(4)2
Avg Revenue beat(4)-5.17%
Min Revenue beat(4)-14.74%
Max Revenue beat(4)3.44%
Revenue beat(8)4
Avg Revenue beat(8)-2.93%
Revenue beat(12)6
Avg Revenue beat(12)-2.42%
Revenue beat(16)10
Avg Revenue beat(16)-1.06%
PT rev (1m)480%
PT rev (3m)443.75%
EPS NQ rev (1m)67.88%
EPS NQ rev (3m)-170%
EPS NY rev (1m)59.58%
EPS NY rev (3m)-148.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.91
P/FCF N/A
P/OCF N/A
P/B 8.09
P/tB 8.09
EV/EBITDA N/A
EPS(TTM)-12.44
EYN/A
EPS(NY)-3.42
Fwd EYN/A
FCF(TTM)-6.61
FCFYN/A
OCF(TTM)-6.56
OCFYN/A
SpS6.42
BVpS1.51
TBVpS1.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.4%
ROE -477.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.92%
FCFM N/A
ROA(3y)-47.4%
ROA(5y)-38.06%
ROE(3y)-228.02%
ROE(5y)-148.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y66.06%
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 7.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.92%
Cap/Sales 0.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.69
Quick Ratio 4.38
Altman-Z -5.07
F-Score4
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)78.75%
Cap/Depr(5y)116.96%
Cap/Sales(3y)3.55%
Cap/Sales(5y)6.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-301.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-840.68%
EPS Next Y72.53%
EPS Next 2Y32.76%
EPS Next 3Y21.75%
EPS Next 5Y14.87%
Revenue 1Y (TTM)-12.8%
Revenue growth 3Y3.48%
Revenue growth 5Y49.74%
Sales Q2Q%-3.41%
Revenue Next Year6.76%
Revenue Next 2Y9.71%
Revenue Next 3Y10.38%
Revenue Next 5Y13.23%
EBIT growth 1Y33.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.7%
EBIT Next 3Y17.05%
EBIT Next 5Y15.99%
FCF growth 1Y13.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.47%
OCF growth 3YN/A
OCF growth 5YN/A